Journal of the Korean Orthopaedic Association (대한정형외과학회지)

Korean Orthopaedic Association (대한정형외과학회)
권호 표지
DOI QR코드

DOI QR Code

Osteonecrosis of the Jaw in a Patient with Osteoporosis Treated with Oral Bisphosphonates

골다공증 환자에서 경구 비스포스포네이트 치료 중 발생한 악골 괴사

  • Choi, Sung-Wook (Department of Orthopedic Surgery, Jeju National University College of Medicine) ;
  • Kim, Sang-Rim (Department of Orthopedic Surgery, Jeju National University College of Medicine) ;
  • Lee, Kwang-Bok (Department of Orthopedic Surgery, Jeju National University College of Medicine) ;
  • Nam, Kwang-Woo (Department of Orthopedic Surgery, Jeju National University College of Medicine) ;
  • Seo, Kyu-Bum (Department of Orthopedic Surgery, Jeju National University College of Medicine) ;
  • Nam, Uk (Department of Orthopedic Surgery, Jeju National University College of Medicine) ;
  • Kim, Hee-Joong (Department of Orthopedic Surgery, Seoul National University College of Medicine)
  • 최성욱 (제주대학교 의과대학 정형외과학교실) ;
  • 김상림 (제주대학교 의과대학 정형외과학교실) ;
  • 이광복 (제주대학교 의과대학 정형외과학교실) ;
  • 남광우 (제주대학교 의과대학 정형외과학교실) ;
  • 서규범 (제주대학교 의과대학 정형외과학교실) ;
  • 남욱 (제주대학교 의과대학 정형외과학교실) ;
  • 김희중 (서울대학교 의과대학 정형외과학교실)
  • Received : 2009.02.25
  • Accepted : 2010.01.09
  • Published : 2010.04.30
⟨ Previous Next ⟩

Abstract

Bisphosphonates are widely used in the management of metastatic bone disease and in the prevention of osteomalacia and osteoporosis. In particular, oral preparations are more commonly used for the prevension and treatment of osteoporosis. Bisphosphonate-related osteonecrosis of the jaws (BRONJ) has been well documented recently in relation to intravenous preparations of the drug. But, a few cases have been reported of oral bisphosphonate-associated osteonecrosis. We could not find any risedronate cases in the Korean medical literature. Here we report a case of BRONJ in a 91-year-old woman patient receiving an oral bisphosphonate (risedronate) for the treatment of osteoporosis.

비스포스포네이트 제제는 골전이가 진행된 암이나 골다공증 및 골형성 부전증 등에 널리 사용되는 약물이다. 특히 경구 비스포스포네이트 제제는 골다공증의 예방 및 치료에 흔히 사용되고 있다. 경정맥 비스포스포네이트 투여 환자에서 악골괴사에 대한 부작용은 잘 알려져 있으나 경구 비스포스포네이트 복용 환자에서는 보고가 많지 않다. 특히 국내에서 리세드로네이트와 관련한 악골괴사에 대한 보고는 없다. 이에 저자들은 91세 여성에서 골다공증 치료를 위해 리세드로네이트 제제를 투약 하던 중 발생한 악골괴사 증례를 경험하여 문헌고찰과 함께 보고하는 바이다.

Keywords

References

  1. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753-61. https://doi.org/10.7326/0003-4819-144-10-200605160-00009
  2. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369- 76. https://doi.org/10.1016/j.joms.2006.11.003
  3. Khosla S, Burr D, Cauley J, et al. Bisphosphonate- associated osteonecrosis of the jaw: report of a task force of the americal society for bone and mineral research. J Bone Miner Res. 2007;22:1479 -91. https://doi.org/10.1359/jbmr.0707onj
  4. Merigo E, Manfredi M, Meleti M, et al. Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed. 2006;77:109-17.
  5. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62: 527-34. https://doi.org/10.1016/j.joms.2004.02.004
  6. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol. 2006;7:508-14. https://doi.org/10.1016/S1470-2045(06)70726-4
  7. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007;29:1548-58. https://doi.org/10.1016/j.clinthera.2007.08.008
  8. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294-301. https://doi.org/10.1210/jc.2004-0952
  9. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonateassociated osteonecrosis: an American academy of oral medicine position paper. J Am Dent Assoc. 2005;136:1658-68. https://doi.org/10.14219/jada.archive.2005.0108
  10. Lam DK, Sandor GK, Holmes HI, Evans AW, Clokie CM. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc. 2007;73:417-22.